Replies to post #9322 on InMed Pharmaceuticals Inc (INM)

[Matilda1]

That’s good news!

[lesgetrich]

Apparently that article only applied to GW Pharmaceuticals drug Epidiolex...

Months after Epidiolex’s release, CBD has become its own unique regulatory challenge after exploding onto the consumer market in recent years. The Agricultural Improvement Act of 2018 (the “2018 Farm Bill”) removed extracts of industrial hemp from Schedule I of the CSA, but officials at FDA have failed to develop guidelines for CBD consumer products.

Currently, all non-Epidiolex CBD products are considered to be illegal by the FDA. Despite significant attempts to change CBD’s status by the industry, FDA has taken the position that CBD’s safety profile has not been established and that consumer products containing the substance are “adulterated” and “misbranded drugs.”

Nothing in the article says that CBD itself was descheduled.